Abstract
The regulation of the delicate balance between the procoagulant and anticoagulant mechanisms is of extreme importance for survival. The procoagulant enzymatic complexes (i.e. prothrombinase, intrinsic tenase and extrinsic tenase) are similar in structure and composed of an enzyme, a cofactor, and the substrate associated on a cell surface in the presence of divalent metal ions. Factor Va and factor VIIIa, which are very similar in structure and function, are required for prothrombinase and intrinsic tenase activities respectively because both cofactors express a dual function in their respective complexes, acting as an enzyme receptor and catalytic effector on the cell surface. The cofactors derive from inactive plasma precursors by regulatory proteolytic events, which involve a-thrombin. In general bleeding tendencies are usually associated with defects in the activation of one of the zymogens or the cofactors of the procoagulant complexes. a-Thrombin, participates in its own down-regulation by binding to the endothelial cell receptor thrombomodulin, and initiating the protein C pathway, which in turn leads to the formation of activated protein C (APC). APC is required for efficient neutralization of factor Va cofactor activity which results in the inactivation of the prothrombinactivating complex. This inactivation can only occur in the presence of the appropriate membrane surface. APC down-regulates the prothrombinase complex by cleaving specific peptide bonds on the heavy chain of factor Va which results in the dissociation of the A2 domain of factor Va from the rest of the molecule. Irregularities in the mechanism of inactivation of factor Va by APC, are associated with thrombotic risk, presumably due to sustained prothrombin activation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Morawitz P. Die Chemie der Blutgemmum. Ergenbn Physiol. 1905;4:307–423.
Kalafatis M, Egan JO, van’t Veer C, Cawthem M, and Mann KG. The regulation of clotting factors. Critical Reviews in Eukariotic Gene Expression 1997;7, 241–280.
Mann KG, Nesheim ME, Church WR, Haley P, and Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood, 1990; 76, 1–16.
Gailani D, Broze GJ Jr: Factor XI activation in a revised model of blood coagulation. Science 1991;253, 909–912.
Owren PA. Parahemophilia: haemorragic diathesis due to absence of a previously unknown clotting factor. Lancet 1947; 1993: 446–448.
Tracy PB, Eide LL, Bowie EJW, Mann KG. Radioimmunoassay of factor V in human plasma and platelets. Blood 1982;60, 59–63.
Tracy PB, Giles AR, Mann KG, Eide LL, Hoogendoom H, and Rivard GE. Factor V (Quebec): a bleeding diathesis associated with a qualitative platelet factor V deficiency. J. Clin. Invest. 1984;74, 1221–1228.
Nesheim ME, Nichols WL, Cole TL, Houston JG, Schenk RB, Mann KG, and Bowie EJW. Isolation and Study of an acquired inhibitor of human coagulation factor V. J. Clin. Invest. 1986 ; 77, 405–415.
Nesheim ME, Taswell JB, Mann KG. The contribution of bovine factor V and factor Va to the activity of prothrombinase. J Biol Chem 1979; 254: 10952–10962.
Cui J, O’Shea KS, Purkayastha A, Sauders TL, Ginsburg D. Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V. Nature 1996;384, 66–68.
Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C. Prediction of a cofactor to activated protein C. Proc. Natl. Acad. Sci. USA 1993;90, 1004–1008.
Bertin RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64–67.
Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777–3785.
Nesheim ME, and Mann KG (1979): Thrombin-catalyzed activation of single factor V. J. Biol. Chem. 254, 1326–1334.
Esmon CT (1979): The subunit structure of thrombin-activated factor V. Isolation of activated factor V, separation of subunits and reconstitution of biological activity. J. Biol. Chem. 254, 964–973.
Suzuki K, Dahiback B, Stenflo J (1982): Thrombin-catalyzed activation of human coagulation factor V. J. Biol. Chem. 257, 6556–6564.
Villoutreix BO, and Dahlback B. Stuctural investigation of the A domains of human blood coagulation factor V by molecular modeling. Protein Science 1998;7, 1317–1325.
Xue J, Kalafatis M, Mann KG. Determination of the disulfide bridges in factor Va light chain. Biochemistry 1993; 32: 5917–5923.
Xue J, Kalafatis M, Silveira JR, Kung C, Mann KG. Determination of the disulfide bridges in factor Va heavy chain. Biochemistry 1994; 33: 13109–13116.
Kalafatis M, Rand MD, Jenny RJ, Ehrlich YH, Mann KG. Phosphorylation of factor Va and factor VIIIa by activated platelets. Blood 1993; 81: 704–719.
Rand MD, Kalafatis M, Mann KG. Platelet coagulation factor Va: The major secretory platelet phosphoprotein. Blood 1994; 83: 2180–2190.
Kalafatis M. Identification and partial characterization of factor Va heavy chain kinase from human platelets. J. Biol. Chem. 1998; 273, 8459–8466.
Hortin GL. Sulfation of tyrosine residues in coagulation factor V. Blood 1993; 76: 946–952.
Esmon CT (1987): The regulation of natural anticoagulant pathways. Science 235 1348–1352.
Lollar P, Parker CG. pH-dependent denaturation of thrombin-activated porcine factor VIII. J. Biol. Chem. 1990; 265, 1688–1692.
Lu D, Kalafatis M, Maim KG, Long GL (1996): Comparison of activated protein S-mediated inactivation of human factor VIII and factor V. Blood 87, 4708–4717.
Kalafatis M, Mann KG. Role of the membrane in the inactivation of factor Va by activated protein C. J Biol Chem 1993; 268: 27246–27257.
Kalafatis M, Rand, MD, Mann KG. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem; 1994; 269: 31869–31880.
van’t Veer Comelis, Golde NJ, Kalafatis M, and Mann KG. Inhibitory Mechanism of the protein C pathway on tissue factor-induced thrombin generation. Synergistic effect in combination with tissue factor pathway inhibitor. J. Biol. Chem 1997; 272, 7983–7994.
Mann KG, Hockin MF, Begin KJ, Kalafatis M Activated protein C cleavage of factor Va leads to dissociation of the A2 domain. J. Biol. Chem. 1997; 272, 20678–20683.
Hockin MF, Kalafatis M, Shatos M, Mann KG. Protein C activation and factor V inactivation on human umbilical vein endothelial cells. Arterioscler. Thromb. Vase. Biol. 1997; 17: 2765–2775.
Kalafatis M, Bertin RM, Rand MD, Mann KG. Characterization of the molecular defect in factor Vim. J Biol Chem 1995; 270: 4053–4057.
Williamson D, Brown K, Luddington R, Baglin C, Baglin T (1998): Factor V Cambridge: A new mutation (Arg306-Thr) associated with resistance to activated protein C. Blood 1998;91: 1140–1144.
Chan WP, Lee CK, Kwong YL, Lam CK, Liang R (1998): A novel mutation of Arg306of factor V gene in Hong Kong Chinese. Blood 1998;91: 1135–1139.
Shen L, Dahlback B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269: 18735–18738.
Varadi K, Rosing J, Tans I, Pabinger I, Keil B, Schwarz HP. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: Influence of the factor VR-906Q mutation. Thromb. Haemost 1996; 76: 208–214.
Kalafatis M and Mann KG. Contributions of the B region of factor V to the inactivation of factor VIII by Activated Protein C (APC). Thromb. Haemost 1999; 82: 742a.
Thorelli E, Kaufman RJ, Dahlback B. Cleavage of factor V at Arg506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552–2558.
Hockin MF, Cawthem KM, Kalafatis M, and Mann KG. A model describing the inactivation of factor Va by APC: bond cleavage, fragment dissociation, and product inhibition. Biochemistry 1999; 38: 6918–6934.
Kalafatis M, Bernardi F, Simioni P, Lunghi B, Girolami A, and Mann KG. Phenotype and Genotype Expression in Pseudohomozygous factor VLEIDENThe need for phenotype analysis. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 336–342.
Nichols WC, Amano K, Cacheris PM, Figueiredo MS, Michaelides K, Schwaab R, Hoyer L, Kaufman RJ, Ginsburg D. Moderation of hemophilia A phenotype by the factor V R506Q mutation. Blood 1996; 88: 1183–1187.
vant’Veer C, Golden NJ, Simioni P, Bertina RM, and Mann KG. An in vitro analysis of the combination of Hemophilia A and factor VLEIDEN. Blood 1997; 90: 3067–3072.
Bajzar L, Kalafatis M, Simioni P, Tracy PB. An antifibrinolytic mechanism describing the prothrombotic effect associated with factor VLEIDEN.J Biol Chem 1996; 271: 22949–22952.
Broze GJ Jr, Higuchi DA (1996): Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hemophilic plasma. Blood; 1996:88, 3815–3823.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer Science+Business Media New York
About this chapter
Cite this chapter
Kalafatis, M., Mann, K.G. (2001). Factor V: Dr. Jeckyll and Mr. Hyde. In: Monroe, D.M., Hedner, U., Hoffman, M.R., Negrier, C., Savidge, G.F., White, G.C. (eds) Hemophilia Care in the New Millennium. Advances in Experimental Medicine and Biology, vol 489. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1277-6_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1277-6_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5474-1
Online ISBN: 978-1-4615-1277-6
eBook Packages: Springer Book Archive